Effects of cerebrolysin on functional outcome of patients with traumatic brain injury: a systematic review and meta-analysis

This article was published in the following Dove Medical Press journal: Neuropsychiatric Disease and Treatment

Fariborz Ghaffarpasand1
Saeed Torabi2
Ali Rasti3
Mohammad Hadi Niakan4
Sara Aghabaklou5
Fatemeh Pakzad6
Maryam Sadat Beheshtian7
Reza Tabrizi8

1Research Center for Neuromodulation and Pain, Shiraz University of Medical Sciences, Shiraz, Iran; 2Department of Anesthesiology and Intensive Care Medicine, University Hospital of Cologne, Cologne, Germany; 3Department of Anesthesiology and Intensive Care Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; 4Department of Neurosurgery, Tehran University of Medical Sciences, Tehran, Iran; 5Department of Anesthesiology, Shiraz University of Medical Sciences, Shiraz, Iran; 6Department of Neurosurgery, Tehran University of Medical Sciences, Tehran, Iran; 7Department of Neurosurgery, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 8Health Policy Research Center, Institute of Health, Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

Background: Traumatic brain injury (TBI) remains a main public health problem being associated with high mortality and morbidity. The functional outcome of TBI remains unfavorable despite several surgical and medical therapies. Cerebrolysin is a neuropeptide with potential neuroregenerative entities.

Objective: The aim of the current systematic review and meta-analysis was to investigate the effects of cerebrolysin on functional outcome in patients with moderate and severe TBI.

Data sources: Online databases used included Medline, Scopus, EMBASE, Google Scholar, Web of Science, and Cochrane Library.

Study eligibility criteria: All the relevant studies with randomized clinical trial and cohort design evaluating the effects of intravenous cerebrolysin vs placebo on functional outcome of patients with TBI within the English literature up to October 2018 were included.

Study appraisal and synthesis methods: The articles were reviewed by two independent authors and the data were extracted to a data sheet. F and Cochran’s Q-statistics were used to assess heterogeneity. Based on the presence of significant heterogeneity across included studies, data were pooled using random-effects model with Dersimonian-Laird method and presented as standardized mean differences (SMDs) and corresponding 95% CI.

Results: Five articles (5,685 participants) were included in the current meta-analysis. The overall pooled findings using random-effects models among patients with TBI indicated that intravenous administration of cerebrolysin significantly increased Glasgow Outcome Scale score (SMD =0.30; 95% CI: 0.18 to 0.42; P<0.001; I²: 87.8%) and decreased modified Rankin Scale score (SMD =−0.29; 95% CI: −0.42 to 0.16; P=0.05; I²: 89.6%).

Limitations: The results are mainly based on cohort studies and there is a lack of clinical trials in the literature. There is also heterogeneity among the studies regarding the dosage and duration of administration and the measurement of functional outcome.

Conclusion: The results of the current study revealed that intravenous administration of cerebrolysin is associated with improved functional outcome in patients with TBI measured by the Glasgow Outcome Scale and the modified Rankin Scale scores.

Keywords: traumatic brain injury, TBI, cerebrolysin, functional outcome, Glasgow Coma Scale, GOS, modified Rankin Scale, mRS

Introduction
Traumatic brain injury (TBI) is among the most common public health problems in both developed and developing countries being associated with high mortality and morbidity and heavy disease burden in all age groups.1,2 According to Center for Disease Control, TBI has been responsible for ~2.5 million emergency department
visits, ~282,000 TBI-related hospitalizations, and ~56,000 TBI-related deaths. The incidence rate is as high as 1.9% in developed countries while it is even higher in developing countries with a TBI-associated mortality rate of 37.7–48.4 per 100,000 populations. The direct and indirect economic burden of the TBI is also a major and growing problem for the policy makers and stockholders with an estimated 4.4 trillion USD in gross domestic product losses during 2015–2030 in developing countries. The current treatment and management of TBI mainly focus on prevention of secondary brain injuries defined as ischemia, infarction, infection, and hydrocephalus along with rehabilitation, cognitive, and physical therapies. Several surgical and medical interventions have been introduced and clinically experienced in patients with TBI with various results; however, none of them have achieved favorable functional outcome and recovery. The research in the field is ongoing with introductions and establishment of new methods and techniques to improve the functional outcome of patients with TBI.

Cerebrolysin is a low molecular neuropeptide with neuroregenerative properties, which is prepared from the extract of the porcine brain tissue with specific laboratory and manufacturing considerations. In vitro and in vivo studies have demonstrated several beneficial effects of cerebrolysin, including decreased excitotoxicity, inhibiting free radical formation, microglial activation/neuroinflammation, and calpain activation/apoptosis. The other interesting effects of the cerebrolysin on neural tissue include inducing neural sprouting in tissue culture, neurotropic effects, and increased neural survival in ischemic conditions. The promising effects of cerebrolysin on regeneration of the neural tissue along with improved clinical and functional outcome of patients with ischemic strokes and neurodegenerative disorders, provided the hypothesis for its application in TBI. During the previous decade, several studies, mostly experimental, tried to investigate the effects of cerebrolysin on functional and clinical outcome of different grades of TBI. Despite the evidence provided from the animal studies were promising in models of TBI, the clinical studies provided controversial results. In addition, there is a scarce of high-quality clinical trials and cohort studies, which makes it hard to provide a level of evidence for application of cerebrolysin in TBI. The aim of the current systematic review and meta-analysis is to review all the available clinical data on cerebrolysin effects on functional outcome of patients with TBI and also analyze the results of cohort studies to reach a clear conclusion and evidence level. The participants are those with TBI, intervention is the administration of intravenous cerebrolysin, comparison is placebo, outcome is the functional outcome, and the study design is the clinical trial and cohort studies on the subject (patients, intervention, comparison, outcome, study design).

Materials and methods

Our study was performed and reported based on the guidelines outlined in the PRISMA.

Search strategy and study selection

To identify prospective studies investigating the impacts of cerebrolysin use on functional outcomes, two authors (F-GH and RT) independently conducted the searches in online databases, including Medline, Scopus, EMBASE, Google Scholar, Web of Science databases, and Cochrane Library from their inception to October 3, 2018. The following key terms were used for database searches: patients (“traumatic brain injury [TBI]” or “brain injury” or “head injury” or “mild TBI” or “moderate TBI” or “severe TBI” or “head trauma” or “brain trauma”), intervention (“cerebrolysin” and “intake” or “use” or “administration” or “application”), and functional outcomes (“Glasgow Outcome Scale [GOS]” or “modified Rankin Scale [mRS]” or “Glasgow Outcome Scale extended [GOSE]”). Reference lists of included articles and previous reviews were manually checked to obtain any further relevant studies not catching in electronic searches.

Inclusion and exclusion criteria

Articles were included in our meta-analysis that met the following inclusion criteria: studies published in a peer-reviewed journal, original prospective articles and conducted on humans, investigated the effects of cerebrolysin use on functional outcomes among patients who had any forms of TBI. TBI was recently defined as: “An alteration in brain function, or other evidence of brain pathology, caused by an external force”. The grading was done according to the on admission Glasgow Coma Scale (GCS) score: mild (14 and 15), moderate (9–13), and severe (3–8). Studies reported sufficient data to calculate the mean changes of scales, including GOS and mRS with related SDs between treatment and control groups. All articles including animal or in vitro studies, protocols without findings, congress abstracts without full texts, and articles published in a language other than English were excluded from the current meta-analysis.

Data extraction and statistical analysis

Two independent authors (F-GH and RT) extracted descriptive and numerical data from every included prospective
article using a standard abstraction form of excel sheet. The extracted data for this meta-analysis consisted of the first authors’ name, year of publication, and sample sizes in treatment and control groups, locations where study was conducted, the characteristics of patients, study design, dosage of cerebrolysin, duration of cerebrolysin, type of underlining disease, and functional outcomes of interest, including GOS or/and mRS measures means and SDs from treatment and control groups.

Flowchart of study
The flowchart of current systematic review identification and selection process has been presented in Figure 1. Overall, our initial search for prospective articles yielded a total of 29 reports. After step-by-step screening and reviewing, five prospective articles ultimately met our systematic review and meta-analysis inclusion criteria. Five included articles were consisted 5,685 patients, which were assigned to 765 participants in case group and 4,920 participants in control group. Of these articles, four articles used cohort design and one used randomized clinical trial design. Dosage of cerebrolysin use ranged from 10 to 30 mL/day. The included prospective studies were published between 2005 and 2017. Duration of cerebrolysin use varied from 10 days to 12 months. The Muresanu et al study reported the effects of cerebrolysin use on functional outcomes in varied conditions for duration, dosage, and underlying disease among participants; therefore, we included that article as several different studies. The detailed characteristics of included prospective articles are presented in Table 1.

Statistical analysis
Following extract, the required data, the mean differences with SD of functional outcomes between intervention and control groups were used to pool data. The standardized mean differences (SMDs) with corresponding 95% CI, while adjusting by the method of Hedges g, were estimated as effect sizes using the random-effects model with
Dersimonian–Laird method according to the likely presence of significant heterogeneity across included primary studies. I² and Cochran’s Q-statistics were used to assess heterogeneity. Sensitivity analyses were performed to estimate the impact of one-by-one study on reliability of the total combined SMDs for each of functional outcomes. Furthermore, subgroup analyses were done to assess the source of heterogeneity based on the possible moderator variables, including the following: type of disease (patients with mild TBI vs those with moderate to severe TBI), dosage of cerebrolysin (≤20 vs >20 mL/day), and duration of study (≤10 vs 10–30 vs >30 days). Egger’s and Begg’s tests were applied to examine any potential publication bias in current meta-analysis. All related statistical analyses were calculated with STATA software version 12.0 (Stata Corp., College Station, TX, USA).

Results
The association between cerebrolysin use and functional outcomes
Forest plots demonstrating the impacts of cerebrolysin use on functional outcomes are indicated in Figure 2. Our results showed that cerebrolysin use in patients with TBI significantly increased GOS (SMD = 0.30; 95% CI: 0.18 to 0.42; \( P < 0.001; \) \( I^2: 87.8\% \)), and decreased mRS (SMD = 0.29; 95% CI: -0.42 to 0.16; \( P = 0.05; \) \( I^2: 89.6\% \)) (Table 2).

Sensitivity/subgroup analyses
Sensitivity analyses did not significantly change the overall combined SMDs on functional outcomes. So, the lower and higher pooled SMDs for GOS in the sensitivity analysis were 0.27 (95% CI: 0.15 to 0.39) after removing the study by Muresanu et al.29 and 0.33 (95% CI: 0.21 to 0.44) after removing the study by Asghari et al.31 For mRS, the lower pooled SMD in the sensitivity analysis was -0.34 (95% CI: -0.46 to 0.22) after removing the study by Asghari et al.31 and the higher was -0.26 (95% CI: -0.39 to 0.13) after removing the study by Khalili et al.32 The findings of subgroup analyses indicated that heterogeneity between included studies was not significant both before and after subgroup analysis. However, the detailed results of the subgroup analyses by type of the disease, dosage of the cerebrolysin, and duration of the study are summarized in Table 3.

Publication bias
Egger’s and Begg’s statistics indicated no significant evidence of potential publication bias for meta-analysis estimating the impact of cerebrolysin use on functional outcomes,
**A** Study ID | SMD (95% CI) | Weight % | Country
---|---|---|---
Wong (2005) | 0.83 (0.20 to 1.46) | 2.51 | China
Alvarez (2008) | −0.16 (−0.70 to 0.38) | 3.09 | Spain
Asghari (2014) | −0.81 (−1.37 to −0.24) | 2.94 | Iran
Muresanu (2015) | −0.08 (−0.26 to 0.09) | 7.00 | Romania
Muresanu (2015) | 0.00 (−0.08 to 0.08) | 7.89 | Romania
Muresanu (2015) | 0.43 (0.26 to 0.61) | 7.00 | Romania
Muresanu (2015) | 0.33 (0.24 to 0.41) | 7.89 | Romania
Muresanu (2015) | 0.49 (0.26 to 0.71) | 6.43 | Romania
Muresanu (2015) | 0.32 (0.18 to 0.46) | 7.41 | Romania
Muresanu (2015) | 0.66 (0.43 to 0.88) | 6.41 | Romania
Muresanu (2015) | 0.36 (0.22 to 0.49) | 7.41 | Romania
Muresanu (2015) | 0.46 (0.32 to 0.61) | 7.35 | Romania
Muresanu (2015) | 0.24 (0.08 to 0.39) | 7.25 | Romania
Muresanu (2015) | 0.58 (0.43 to 0.72) | 7.34 | Romania
Muresanu (2015) | 0.25 (0.09 to 0.40) | 7.25 | Romania
Khalili (2017) | 0.46 (0.11 to 0.81) | 4.84 | Iran

**Overall (I²=87.8%, P=0.000)** | 0.30 (0.18 to 0.42) | 100 |  

**B** Study ID | SMD (95% CI) | Weight % | Country
---|---|---|---
Wong (2005) | −0.67 (−1.29 to −0.05) | 2.81 | China
Alvarez (2008) | 0.18 (−0.36 to 0.72) | 3.35 | Spain
Asghari (2014) | 1.51 (0.89 to 2.12) | 2.85 | Iran
Muresanu (2015) | 0.01 (−0.16 to 0.19) | 6.99 | Romania
Muresanu (2015) | 0.01 (−0.07 to 0.10) | 7.74 | Romania
Muresanu (2015) | −0.37 (−0.55 to −0.20) | 6.99 | Romania
Muresanu (2015) | −0.25 (−0.33 to −0.17) | 7.74 | Romania
Muresanu (2015) | −0.65 (−0.87 to −0.42) | 6.48 | Romania
Muresanu (2015) | −0.47 (−0.61 to −0.33) | 7.33 | Romania
Muresanu (2015) | −0.58 (−0.80 to −0.36) | 6.48 | Romania
Muresanu (2015) | −0.41 (−0.55 to −0.27) | 7.34 | Romania
Muresanu (2015) | −0.42 (−0.56 to −0.27) | 7.29 | Romania
Muresanu (2015) | −0.20 (−0.36 to −0.05) | 7.20 | Romania
Muresanu (2015) | −0.47 (−0.61 to −0.33) | 7.28 | Romania
Muresanu (2015) | −0.23 (−0.39 to −0.08) | 7.20 | Romania
Khalili (2017) | −0.84 (−1.20 to −0.47) | 4.94 | Iran

**Overall (I²=89.6%, P=0.000)** | −0.29 (−0.42 to −0.16) | 100 |  

Figure 2 Meta-analysis on clinical outcomes (SMD estimates [95% CI]) for GOS (A) and mRS (B) scores for patients treated with cerebrolysin and control groups. 

**Note:** Weights are from random-effects analysis. 

**Abbreviations:** GOS, Glasgow Outcome Scale; mRS, modified Rankin Scale; SMD, standardized mean difference.
including GOS (Begg’s test \( P=0.97 \) and Egger’s test \( P=0.73 \)) and mRS (Begg’s test \( P=0.50 \), Egger’s test \( P=0.32 \)).

**Discussion**

We ran this systematic review and meta-analysis to assess the efficacy of the cerebrolysin treatment on functional outcome of patients with TBI. The results of the current study demonstrate that intravenous administration of cerebrolysin after TBI is associated with improved functional recovery in patients with different grades of the TBI (mild to severe). The functional outcome in the included studies was GOS and mRS and other indices, such as cognitive functions and memory could not be included in the pooled analysis due to lack of homogeneity and availability. The study demonstrates large heterogeneity in the performed studies and reported outcomes. Also, lack of standard clinical trials decreases the level of evidence for this therapy in patients with TBI. The efficacy and safety of cerebrolysin for management of TBI has been tested in several animal studies with favorable results.\(^{19-22}\) However, the clinical studies are scarce on

### Table 2 The overall pooled SMD for cerebrolysin treatment across all included studies

<table>
<thead>
<tr>
<th>Clinical outcomes</th>
<th>Number of studies</th>
<th>Pooled SMDs</th>
<th>95% CI</th>
<th>( P )-value</th>
<th>Heterogeneity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>( I^2 ) (%)</td>
</tr>
<tr>
<td>GOS</td>
<td>16</td>
<td>0.3</td>
<td>0.18 to 0.42</td>
<td>(&lt;0.001)</td>
<td>87.8</td>
</tr>
<tr>
<td>mRS</td>
<td>16</td>
<td>-0.29</td>
<td>-0.42 to 0.16</td>
<td>0.05</td>
<td>89.6</td>
</tr>
</tbody>
</table>

**Abbreviations:** GOS, Glasgow Outcome Scale; mRS, modified Rankin Scale; SMD, standardized mean difference.

### Table 3 The association between cerebrolysin use and clinical outcomes in patients with traumatic brain injury based on subgroup analysis

<table>
<thead>
<tr>
<th>Variables</th>
<th>( K^* )</th>
<th>( I^2 ) (%)</th>
<th>( Q )-test</th>
<th>SMD (95% CI)</th>
<th>( P )-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GOS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>16</td>
<td>87.8</td>
<td>123.32</td>
<td>0.30 (0.18 to 0.42)</td>
<td>(&lt;0.001)</td>
</tr>
<tr>
<td>Type of disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild TBI</td>
<td>4</td>
<td>93.4</td>
<td>45.76</td>
<td>0.17 (-0.06 to 0.40)</td>
<td>0.14</td>
</tr>
<tr>
<td>Moderate to severe TBI</td>
<td>12</td>
<td>76.0</td>
<td>45.79</td>
<td>0.36 (0.24 to 0.49)</td>
<td>(&lt;0.001)</td>
</tr>
<tr>
<td>Dosage of cerebrolysin (mL/day)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( &gt;20 )</td>
<td>7</td>
<td>86.1</td>
<td>43.32</td>
<td>0.45 (0.25 to 0.65)</td>
<td>(&lt;0.001)</td>
</tr>
<tr>
<td>( \leq20 )</td>
<td>9</td>
<td>85.1</td>
<td>54.96</td>
<td>0.20 (0.06 to 0.34)</td>
<td>(&lt;0.01)</td>
</tr>
<tr>
<td>Duration of study (days)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( \leq10 )</td>
<td>3</td>
<td>67.6</td>
<td>6.18</td>
<td>0.37 (-0.13 to 0.87)</td>
<td>0.14</td>
</tr>
<tr>
<td>( 10-30 )</td>
<td>6</td>
<td>90.6</td>
<td>53.14</td>
<td>0.23 (0.04 to 0.42)</td>
<td>(&lt;0.001)</td>
</tr>
<tr>
<td>( &gt;30 )</td>
<td>3</td>
<td>67.6</td>
<td>6.18</td>
<td>0.37 (-0.13 to 0.87)</td>
<td>0.14</td>
</tr>
<tr>
<td><strong>mRS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>16</td>
<td>89.6</td>
<td>143.67</td>
<td>-0.29 (-0.42 to -0.16)</td>
<td>0.05</td>
</tr>
<tr>
<td>Type of disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mild TBI</td>
<td>4</td>
<td>89.7</td>
<td>29.16</td>
<td>-0.15 (-0.33 to 0.04)</td>
<td>0.11</td>
</tr>
<tr>
<td>Moderate to severe TBI</td>
<td>12</td>
<td>83.7</td>
<td>67.52</td>
<td>-0.36 (-0.51 to -0.21)</td>
<td>(&lt;0.001)</td>
</tr>
<tr>
<td>Dosage of cerebrolysin (mL/day)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( &gt;20 )</td>
<td>7</td>
<td>80.4</td>
<td>30.60</td>
<td>-0.42 (-0.59 to -0.25)</td>
<td>(&lt;0.001)</td>
</tr>
<tr>
<td>( \leq20 )</td>
<td>9</td>
<td>89.6</td>
<td>92.99</td>
<td>-0.29 (-0.42 to -0.16)</td>
<td>0.03</td>
</tr>
<tr>
<td>Duration of study (days)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>( \leq10 )</td>
<td>7</td>
<td>87.8</td>
<td>49.05</td>
<td>-0.28 (-0.45 to -0.05)</td>
<td>(&lt;0.01)</td>
</tr>
<tr>
<td>( 0-30 )</td>
<td>6</td>
<td>92.8</td>
<td>69.22</td>
<td>-0.28 (-0.49 to -0.06)</td>
<td>0.01</td>
</tr>
<tr>
<td>( &gt;30 )</td>
<td>3</td>
<td>97.2</td>
<td>9.47</td>
<td>-0.46 (-1.09 to 0.17)</td>
<td>0.15</td>
</tr>
</tbody>
</table>

**Note:** \( K^* \) denotes number of SMD included.

**Abbreviations:** GOS, Glasgow Outcome Scale; mRS, modified Rankin Scale; SMD, standardized mean differences; TBI, traumatic brain injury.
the subject and the literature only includes limited number of standard studies addressing the effectiveness of the cerebrolysin on functional recovery after various grades of TBI. The studies are mostly prospective or retrospective cohorts and only limited randomized clinical trials are available. Currently, a large multicenter, placebo-controlled, randomized clinical trial is underway to address the subject but the results are not available yet.

The heterogeneity in the clinical studies could be classified in several fields. First, the inclusion criteria for the patients with TBI vary between these studies. While some authors have included only patients with severe TBI, other included moderate and severe TBI patients and Chen et al studied only mild TBI patients. These heterogeneous inclusion criteria led to limited power of analysis because the management and outcome of patients depend on the severity of TBI. The baseline GCS has been demonstrated to be the most important predictor of functional outcome in patients with TBI. Thus, cerebrolysin could have various effects on the outcome of patients with different grades of TBI. The other factor contributing to heterogeneity of the studies is the dosage and duration of the treatment. Some studies administered the cerebrolysin in 10 mL/day dosage while other used the 20–30 mL/day dosages. The highest dosage (50 mL/day) was given by Wong et al. The duration also varied between 5 and 30 days. As cerebrolysin is a newly investigated medication, the appropriate dosage and duration should be elucidated according to the pharmacokinetics and the clinical studies. The current treatment regimens are mainly based on the regimens that are given to the patients with ischemic stroke, Alzheimer’s, and Parkinson’s disease. Kö nig et al also reported the beneficial effects of cerebrolysin given at the dosage of 50 mL/day for 21 days in patients with various grades of TBI measured by serial GCS and cognitive tests. Thus, the standard treatment protocol for TBI should be established based on the ongoing research. The Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery, which is underway, is using a 50 mg/day dosage over a 10-day period. And finally, the outcome measures of functional recovery are heterogeneous between the studies. Most of the studies report the GOS, GOSE, and mRS while Chen et al reported Mini-Mental State Examination (MMSE), and Cognitive Abilities Screening Instrument (CASI). This is due the fact that patients with mild TBI were included and GOS and mRS have limited value in evaluating the functional recovery in these patients. Thus, cognitive measurement outcomes, such as MMSE and CASI should be included. In addition, some other studies used the EEG findings to determine the effects of cerebrolysin on outcome in patients with mild TBI. These variations reduced the number of studies that could be included in the meta-analysis, although there was heterogeneity between the studies. The findings of subgroup analyses indicated that heterogeneity between included studies had no significant effects on the outcome measures before and after subgroup analysis. Furthermore, all the studies, which were not included, demonstrated that cerebrolysin therapy is associated with improved functional, cognitive, and electrical outcomes in patients with mild, moderate, and severe TBI.

The neuroprotective and neuroregenerative properties of the cerebrolysin have increased its use in different neurologic and neurosurgical conditions. Recently, Hassanein et al demonstrated that cerebrolysin administration dramatically improved the communication defects of the neonates with severe perinatal brain insults. These results along with those previously reported on effectiveness of cerebrolysin on regeneration of injured nerves suggest that the proposed treatment could be used along with stem cell therapies to induce neuroregeneration. The horizons of neural therapy with stem cell and regenerative medicine could be established by use of cerebrolysin. Most recently, Zhang et al reported the results of a prospective, randomized, placebo-controlled study of cerebrolysin dose-dependent effects in animal model of mild TBI. They demonstrated that administration of cerebrolysin at doses of 0.8–7.5 mL/kg, administered 4 hours after mild TBI and then once daily for a total of 10 consecutive days, improved functional outcomes 3 months after injury. In a similar study, Sharma et al investigated the beneficial effects of cerebrolysin therapy on pathophysiological aspects of TBI. They demonstrated that administration of cerebrolysin 5 minutes or 1 hour after TBI reduced blood–brain barrier permeability changes, attenuated brain pathology and brain edema, and mitigated functional deficits. However, administration of cerebrolysin 2 hours after the injury had no beneficial effects. These findings suggest timely intervention with cerebrolysin to achieve appropriate functional outcome. Taking all these together, it could be concluded that timely and dose-dependent effects of cerebrolysin should be considered in designing trials in TBI. The results of the current meta-analysis also confirm the efficacy of the cerebrolysin therapy in improving the functional outcome of patients with various grades of TBI.

**Conclusion**

Intravenous cerebrolysin administration has been associated with improved functional recovery after TBI as measured by...
mRS and GOS. There is a significant heterogeneity in dosage and duration of therapy as well as interval between the injury and treatment application, which limits the effect analysis. In addition, the various grades of TBI (mild, moderate, and severe) seem to benefit from cerebrolysin therapy after the injury with regard to the functional outcome indices. The lack of standard and high quality randomized clinical trials limits the clinical application and final conclusion on the efficacy of cerebrolysin in patients with TBI and the level of evidence remains low in results. Based on the results of the current study, intravenous could be recommended for treatment of patients with different grades of TBI with level II of evidence. More randomized clinical trials are recommended to elucidate the issue.

Acknowledgment
We would like to acknowledge the Diba Negar Research Institute for editorial assistance and improving the style and English in the manuscript.

Disclosure
The authors report no conflicts of interest in this work.

References


